ArticleJournal of ovarian research2025
Diagnostic performance of circulating EpCAM+ and CD45+ extracellular vesicles in platinum-sensitivity in high-grade serous ovarian cancer: a pilot study.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Large extracellular vesicles and blebbisomes in cancer: emerging and translational opportunities highlights.Cell communication and signaling : CCS · 2026Review
- Targeting MFF succinylation: a novel therapeutic strategy for premature ovarian insufficiency by restoring mitochondrial dynamics in granulosa cells.Journal of ovarian research · 2026Review
- Small Extracellular Vesicles: Unraveling Their Roles in Ovarian Cancer Progression and Tapping Into Clinical Application Potential.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlatinum-resistant high-grade serous ovarian cancer (HGSOC) is a fatal disease. The main goal of current study is to develop new strategies to predict platinum resistance, moving towards personalized therapy. Currently, there are no validated biomarkers able to predict at diagnosis platinum resistance. Circulating tumor-derived extracellular vesicles (EVs) represent a liquid biopsy of the tumor of origin and reflect its biological profile. EpCAM-expressing EVs are largely used biomarkers of epithelial cancers in translational research. Aim of this study was to quantify, by nano-flow cytometry, circulating EpCAM+ EVs in patients with histologically confirmed diagnosis of HGSOC FIGO stage III/IV, before and after intravenous administration of the first dose of chemotherapy with paclitaxel and carboplatin, and correlate EVs levels to platinum-sensitivity. As comparison, leukocyte-derived EVs were also assessed using the pan-leukocyte marker CD45.
resultsPatients with platinum-sensitive HGSOC showed significantly lower pre-chemotherapy circulating levels of both EpCAM+ and CD45+ EVs compared to platinum-resistant cases (p<0.01). Platinum-sensitive patients displayed significantly higher levels of circulating EpCAM+ and CD45+ EVs 21 days post administration of the first dose of chemotherapy compared to pre-treatment levels (p<0.05 and p<0.01, respectively). Platinum-resistant and platinum-refractory patients showed significantly higher EpCAM
conclusionsTumor-derived EVs are valuable candidate biomarkers for early prediction of platinum resistance and need to be investigated in larger prospective clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.